Vinorelbine in Mesothelioma (Vim): a Randomised Phase II Trial of Oral Vinorelbine as Second-Line Therapy for Patients with Malignant Pleural Mesothelioma (Mpm) Expressing Brca1
Latest Information Update: 06 Nov 2012
At a glance
- Drugs Vinorelbine (Primary)
- Indications Malignant-mesothelioma
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms VIM
- 06 Nov 2012 New trial record